{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:32:29Z","timestamp":1761989549064,"version":"3.40.5"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Context<\/jats:title><jats:p>Serious adverse events related to the use of domperidone and metoclopramide have been consistently reported in the literature for many years. This led to a restriction of their use in the early 2010s.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The main objective was to analyse the evolution of antiemetic prescription rate in French general practise between 2006 and 2016. The secondary objectives were to highlight prescription transfers for metopimazine and to quantify the impact on health expenditures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>All patients from a representative sample of a national administrative claims database, the French national health insurance database, were included between 2006 and 2016. Trends in annual anti\u2010emetic prescription rates by general practitioners were analysed using logistic regression models adjusted for age, gender and the existence of cancer. The cost of theses changing prescription habits was quantified via M\u00e9dic'AM, a public drug expenditure database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Around 669\u2009020 individuals were included with a mean 8\u2010year follow\u2010up; 48\u2009634 patients received an anti\u2010emetic at least once between 2006 and 2016. Prescription rates for all antiemetics decreased significantly from 2.1% to 0.4%, especially for metoclopramide from 0.5% to 0.1%, for domperidone from 1.5% to 0.1% and for metopimazine from 0.4% to 0.2%, which is not in favour of prescription transfers. Expenses fell from 30\u2009million euros in 2006 to 10\u2009million in 2016.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Decreases in anti\u2010emetic prescription rates and public health expenditures preceded the publication of official recommendations to reduce the use of metoclopramide and domperidone, without prescription transfers for metopimazine.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.5170","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T15:19:32Z","timestamp":1604675972000},"page":"418-425","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The evolution of <scp>anti\u2010emetic<\/scp> prescriptions in primary care, between 2006 and 2016"],"prefix":"10.1002","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3031-5604","authenticated-orcid":false,"given":"David","family":"De Bandt","sequence":"first","affiliation":[{"name":"Department of Family Medicine, Faculty of Health Sciences, Simone Veil University of Versailles  Saint\u2010Quentin\u2010en\u2010Yvelines France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Safsaf","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Faculty of Health Sciences, Simone Veil University of Versailles  Saint\u2010Quentin\u2010en\u2010Yvelines France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bastien","family":"Bourrion","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Faculty of Health Sciences, Simone Veil University of Versailles  Saint\u2010Quentin\u2010en\u2010Yvelines France"},{"name":"Centre for Research in Epidemiology and Population Health, the French National Institute of Health and Medical Research (INSERM U 1018) University of Versailles, Saint\u2010Quentin\u2010en\u2010Yvelines, University Paris\u2010Sud  Villejuif France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8117-7016","authenticated-orcid":false,"given":"Mathilde","family":"Francois","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Faculty of Health Sciences, Simone Veil University of Versailles  Saint\u2010Quentin\u2010en\u2010Yvelines France"},{"name":"Centre for Research in Epidemiology and Population Health, the French National Institute of Health and Medical Research (INSERM U 1018) University of Versailles, Saint\u2010Quentin\u2010en\u2010Yvelines, University Paris\u2010Sud  Villejuif France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"key":"e_1_2_9_2_1","article-title":"Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents","volume":"9","author":"Fedorowicz Z","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_3_1","unstructured":"BaderC GlanardA Vignand\u2010CourtinC.Prise en charge des naus\u00e9es et vomissements gravidiques chez la femme enceinte.2012;31:5."},{"key":"e_1_2_9_4_1","unstructured":"M\u00e9dicaments Anti\u00e9m\u00e9tiques Dans le Traitement Symptomatique des Naus\u00e9es et Vomissements [Internet].Haute Autorit\u00e9 de Sant\u00e9.https:\/\/www.has-sante.fr\/jcms\/c_2966830\/fr\/medicaments-antiemetiques-dans-le-traitement-symptomatique-des-nausees-et-vomissements. Cit\u00e9 Ao\u00fbt 23 2020"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3486"},{"volume-title":"Harrison's Principles of Internal Medicine","year":"1995","author":"Kasper F","key":"e_1_2_9_6_1"},{"volume-title":"Drug Evaluation Annual","year":"1995","key":"e_1_2_9_7_1"},{"issue":"6","key":"e_1_2_9_8_1","first-page":"829","article-title":"Review of a new gastrointestinal drug\u2014metoclopramide","volume":"38","author":"Ponte CD","year":"1981","journal-title":"Am J Hosp Pharm"},{"key":"e_1_2_9_9_1","unstructured":"Recommandations du Comit\u00e9 des M\u00e9dicaments \u00e0 Usage Humain (CHMP) Relatives \u00e0 L'utilisation du M\u00e9toclopramide du K\u00e9toconazole par voie Orale et des Incr\u00e9tinomim\u00e9tiques\u2014Point D'information\u2014ANSM: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9 [Internet].2013.https:\/\/ansm.sante.fr\/S\u2010informer\/Travaux\u2010de\u2010l\u2010Agence\u2010Europeenne\u2010des\u2010Medicaments\u2010EMA\u2010Comite\u2010des\u2010medicaments\u2010a\u2010usage\u2010humain\u2010CHMP\/Recommandations\u2010du\u2010Comite\u2010des\u2010medicaments\u2010a\u2010usage\u2010humain\u2010CHMP\u2010relatives\u2010a\u2010l\u2010utilisation\u2010du\u2010metoclopramide\u2010du\u2010ketoconazole\u2010par\u2010voie\u2010orale\u2010et\u2010des\u2010incretinomimetiques\u2010Point\u2010d\u2010information. Cit\u00e9 Juin 23 2019"},{"key":"e_1_2_9_10_1","unstructured":"Metoclopramide only Containing Medicinal Products [Internet].European Medicines Agency. Report No.: EMEA\/H\/A\u201031\/1321. 2013.https:\/\/www.ema.europa.eu\/en\/documents\/referral\/assessment-report-metoclopramide-containing-medicines_en.pdf"},{"key":"e_1_2_9_11_1","unstructured":"Domperidone\u2010Containing Medicines [Internet].European Medicines Agency. 2018.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/domperidone-containing-medicines. Cit\u00e9 Juin 23 2019"},{"key":"e_1_2_9_12_1","unstructured":"Agence F\u00e9d\u00e9rale des M\u00e9dicaments et des Produits de Sant\u00e9. Communication Directe Adress\u00e9e aux Professionnels de la Sant\u00e9 M\u00e9dicaments Contenant de la Domp\u00e9ridone Nouvelles Recommandations Visant \u00e0 Limiter les Risques Cardiaques [Internet].2014.https:\/\/www.afmps.be\/sites\/default\/files\/downloads\/DHPC-Domperidone-FR-Website.pdf"},{"key":"e_1_2_9_13_1","unstructured":"De Nouvelles Recommandations Pour Minimiser les Risques Cardiaques des M\u00e9dicaments Contenant de la Domp\u00e9ridone\u2014Point D'information\u2014ANSM: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9 [Internet].2014.https:\/\/www.ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/De-nouvelles-recommandations-pour-minimiser-les-risques-cardiaques-des-medicaments-contenant-de-la-domperidone-Point-d-Information. Cit\u00e9 Juin 23 2019"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2016-000875.297"},{"key":"e_1_2_9_15_1","unstructured":"Commissioner Office of the Safety Alerts for Human Medical Products\u2014Inapsine (droperidol) Dear Healthcare Professional Letter Dec 2001 [Internet]. Office of the Commissioner.https:\/\/wayback.archive-it.org\/7993\/20170113165136\/http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm173778.htm. Cit\u00e9 Ao\u00fbt 23 2020"},{"key":"e_1_2_9_16_1","unstructured":"U.S. Food and Drug Administration.FDA Requires Boxed Warning and Risk Mitigation Strategy for Metoclopramide\u2010Containing Drugs [Internet].2009.www.fda.gov. Cit\u00e9 Mars 5 2009"},{"key":"e_1_2_9_17_1","first-page":"45","article-title":"Prolong QT interval and \u00ab torsades de pointes \u00bb associated with different group of drugs","volume":"153","author":"Gongadze N","year":"2007","journal-title":"Georgian Med News"},{"issue":"274","key":"e_1_2_9_18_1","first-page":"508","article-title":"Domp\u00e9ridone et mort subite","volume":"26","year":"2006","journal-title":"Rev Prescrire"},{"key":"e_1_2_9_19_1","unstructured":"Netgen.Utilisation des Traitements Antinaus\u00e9eux [Internet].Revue M\u00e9dicale Suisse.https:\/\/www.revmed.ch\/RMS\/2001\/RMS-2346\/21380. Cit\u00e9 Ao\u00fbt 23 2020"},{"volume-title":"Sp\u00e9cialit\u00e9s Examin\u00e9es Dans le Cadre de la R\u00e9\u00e9valuation du Service M\u00e9dical Rendu des Sp\u00e9cialit\u00e9s \u00e0 Base de Domp\u00e9ridone","year":"2005","key":"e_1_2_9_20_1"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/archfami.1.2.271"},{"issue":"1","key":"e_1_2_9_22_1","first-page":"3","article-title":"The effects of the FDA warning on the use of droperidol by U.S. emergency physicians","volume":"4","author":"Richards JR","year":"2003","journal-title":"Calif J Emerg Med"},{"key":"e_1_2_9_23_1","article-title":"The Echantillon g\u00e9n\u00e9raliste de b\u00e9n\u00e9ficiaires: representativeness, scope and limits","volume":"40","author":"Roquefeuil L","year":"2009","journal-title":"Prat Organ Soins"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respe.2017.05.004"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejsp.674"},{"key":"e_1_2_9_26_1","unstructured":"M\u00e9dicaments Rembours\u00e9s par l'Assurance Maladie\u2014data.gouv.fr [Internet].\/fr\/datasets\/medicaments-rembourses-par-lassurance-maladie\/.Cit\u00e9 Juin 23 2019"},{"issue":"3","key":"e_1_2_9_27_1","first-page":"159","article-title":"Gastroenteritis in children","volume":"99","author":"Hartman S","year":"2019","journal-title":"Am Fam Physician"},{"key":"e_1_2_9_28_1","unstructured":"M\u00e9dicaments \u00e0 Base de Domp\u00e9ridone et S\u00e9curit\u00e9 D'emploi Cardiovasculaire\u2014Lettre aux Professionnels de Sant\u00e9\u2014ANSM: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9 [Internet].2011.https:\/\/ansm.sante.fr\/S\u2010informer\/Informations\u2010de\u2010securite\u2010Lettres\u2010aux\u2010professionnels\u2010de\u2010sante\/Medicaments\u2010a\u2010base\u2010de\u2010domperidone\u2010et\u2010securite\u2010d\u2010emploi\u2010cardiovasculaire\u2010Lettre\u2010aux\u2010professionnels\u2010de\u2010sante. Cit\u00e9 Juin 23 2019"},{"key":"e_1_2_9_29_1","unstructured":"Sp\u00e9cialit\u00e9s \u00e0 Base de M\u00e9toclopramide: Actualisation des Indications et de la Posologie Pour Diminuer le Risque (Principalement Neurologique) D'effets Ind\u00e9sirables\u2014Lettre aux Professionnels de Sant\u00e9\u2014ANSM: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9 [Internet].2014.https:\/\/ansm.sante.fr\/S\u2010informer\/Informations\u2010de\u2010securite\u2010Lettres\u2010aux\u2010professionnels\u2010de\u2010sante\/Specialites\u2010a\u2010base\u2010de\u2010metoclopramide\u2010actualisation\u2010des\u2010indications\u2010et\u2010de\u2010la\u2010posologie\u2010pour\u2010diminuer\u2010le\u2010risque\u2010principalement\u2010neurologique\u2010d\u2010effets\u2010indesirables\u2010Lettre\u2010aux\u2010professionnels\u2010de\u2010sante. Cit\u00e9 Juin 23 2019"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.300"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-017-0481-7"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.2361"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00430.x"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5170","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.5170","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T23:26:08Z","timestamp":1693697168000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,3]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1002\/pds.5170"],"URL":"https:\/\/doi.org\/10.1002\/pds.5170","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"type":"print","value":"1053-8569"},{"type":"electronic","value":"1099-1557"}],"subject":[],"published":{"date-parts":[[2020,12,3]]},"assertion":[{"value":"2020-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}